Lori Adels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lori adels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lori Adels Today - Breaking & Trending Today

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™


Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. The IDE approval follows the receipt of Breakthrough Device Designation from the FDA in February 2021.
We are eager to move ahead with this important trial and anticipate patient enrollment beginning within the next three months, stated Dr. Stephen Griffin, President of Cerus Endovascular. The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval. Given the real-world patient outcomes we have experienced in Europe, where the Contour Neurovascular Syste ....

United Kingdom , Sam Milstein , Stephen Griffin , Lori Adels , Cerus Endovascular , Prnewswire Cerus Endovascular Ltd , Cerus Endovascular Ltd , Drug Administration , Rx Communications Group , Endovascular Ltd , Investigational Device Exemption , Contour Neurovascular System , Breakthrough Device Designation , Premarket Approval , Ceru Chairman , Chief Compliance Officer , Neqstent Coil Assisted Flow Diverter , Communications Group , ஒன்றுபட்டது கிஂக்டம் , சாம் மில்ஸ்டீன் , ஸ்டீபன் கிரிஃபின் , ர்க்ஸ் தகவல்தொடர்புகள் குழு , எண்டோவாஸ்குலர் லிமிடெட் , திருப்புமுனை சாதனம் பதவி , தலைமை இணக்கம் அதிகாரி , தகவல்தொடர்புகள் குழு ,

Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™


Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™
News provided by
Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.
Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. The designation expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly. ....

United Kingdom , Sam Milstein , Stephen Griffin , Lori Adels , Cerus Endovascular , Prnewswire Cerus Endovascular Ltd , Cerus Endovascular Ltd , Drug Administration , Rx Communications Group , Endovascular Ltd , Breakthrough Device Designation , Contour Neurovascular System , Device Designation , Chief Compliance Officer , Investigational Device Exemption , Ceru Chairman , Contour System , Neqstent Coil Assisted Flow Diverter , Communications Group , ஒன்றுபட்டது கிஂக்டம் , சாம் மில்ஸ்டீன் , ஸ்டீபன் கிரிஃபின் , ர்க்ஸ் தகவல்தொடர்புகள் குழு , எண்டோவாஸ்குலர் லிமிடெட் , திருப்புமுனை சாதனம் பதவி , சாதனம் பதவி ,